Previous close | 3.9900 |
Open | 3.9700 |
Bid | 3.7600 x 1300 |
Ask | 4.0000 x 2200 |
Day's range | 3.7596 - 4.0700 |
52-week range | 2.3550 - 11.3300 |
Volume | |
Avg. volume | 947,347 |
Market cap | 221.546M |
Beta (5Y monthly) | 1.64 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.1060 |
Earnings date | 03 Aug 2022 - 08 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 19.88 |
Even if it's not a huge purchase, we think it was good to see that Todd Brady, the CEO, President & Director of Aldeyra...
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
LEXINGTON, Mass., June 09, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside chat at the Jefferies Global Healthcare Conference.